Annelie
Annelie Abrahamsson, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20100287631 | WNT PATHWAY MUTATIONS IN CANCER STEM CELLS - Cancer specific splicing events in the Wnt/β-catenin signaling pathway are associated with progression of myelogenous leukemia. Misspliced genes of interest include GSK3β. In some embodiments of the invention, polynucleotides are provided that correspond to misspliced GSK3β transcripts associated with cancer. Such transcripts are characterized by a deletion of exon (8), and particularly in exon (8) and (9). Detection of such transcripts in cells is indicative of the presence of leukemia, and particularly of the presence of leukemia stem cells. In other embodiments, polypeptides are provided that are encoded by misspliced GSK3β transcripts associated with cancer. Such polypeptides are useful as diagnostic markers for cancer, and as a target for screening of therapeutic agents. Animal models comprising a human LSC having a misspliced GSK3b transcript provide a useful model for leukemia, for drug/gene screening in the prevention and treatment of leukemia in humans, etc. | 11-11-2010 |
Annelie Carlsbecker, Uppsala SE
Patent application number | Description | Published |
---|---|---|
20160002659 | POLYPEPTIDE - The present invention relates to a polypeptide, or a fragment thereof, capable of enhancing callose biosynthesis and/or accumulation, wherein at least one of the conserved amino acid residues selected from the group consisting of residue corresponding to R84 of SEQ ID NO: 1, residue corresponding to R1926 or SEQ ID NO: 1 and residue corresponding to P189 of SEQ ID NO: 1, of the polypeptide or a fragment thereof, is modified by a mutation selected from the group consisting of substitution and deletion. | 01-07-2016 |
Annelie Doehling, Muenster DE
Patent application number | Description | Published |
---|---|---|
20090172896 | Colorant with nacreous luster for keratin fibers - The object of the present application is a dye carrier composition containing oxidative and/or non-oxidative dyes as well as | 07-09-2009 |
Annelie Schairer, Escondido, CA US
Patent application number | Description | Published |
---|---|---|
20110059448 | COMPOSITIONS AND METHODS FOR DETERMINING CANCER STEM CELL SELF-RENEWAL POTENTIAL - In alternative embodiments, the invention provides compositions and methods for determining the self-renewal potential of a cancer stem cell (CSC) through analysis of the cross-talk between cell self-renewal pathways leading to deregulation and enhanced self-renewal of the CSC, or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC, the method comprising detecting and quantifying in CSCs one or more B-cell lymphoma-2 (Bcl-2) family protein isoform(s) or transcripts (mRNAs, messages) encoding one or more Bcl-2 family protein(s) or protein isoform(s) thereof. In alternative embodiments, the invention provides compositions and methods to determine and measure the levels of Wnt, glycogen synthase kinase-3 beta (GSK-3 beta), glycogen synthase kinase-3 alpha (GSK-3 alpha), and/or Sonic Hedgehog Homolog (SHH or Shh) family proteins and alternatively spliced transcripts (mRNAs), and Wnt, GSK3beta, GSK3alpha and/or Shh family protein and alternatively spliced transcript ratios in cancer cells, e.g., stem cells, e.g., CSCs, for diagnostic, drug discovery and prognostic purposes. | 03-10-2011 |
Annelie Schairer, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20110243853 | MODELS OF ERYTHROPOIESIS - Non human animal models are provided for diseases involving erythroid function, particularly myeloproliferative disease. The models are useful for testing and screening of biologically active agents that affect erythropoiesis, and erythroid function. In the animal models of the invention, a hematopoietic stem or progenitor cell (HSC) population that has been genetically altered by the introduction of a mutant JAK2 coding sequence is transplanted into an immunocompromised, xenogeneic, non-human recipient. The recipient animal is engrafted with the cell population at a high frequency, and develops a myeloproliferative disorder characterized by polycythemia. | 10-06-2011 |